The Role of Gr1+ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice

  • Hu C
  • Du W
  • Zhang X
  • et al.
32Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Studies suggest that Gr1+CD11b+ cells have immunoregulatory function, and these cells may play an important role in autoimmune diseases. In this study, we investigated the regulatory role of Gr1+CD11b+ cells in protecting against type 1 diabetes in NOD mice. In this study, we showed that temporary B cell depletion induced the expansion of Gr1+CD11b+ cells. Gr1+CD11b+ cells not only directly suppress diabetogenic T cell function but also can induce regulatory T cell differentiation in a TGF-β–dependent manner. Furthermore, we found that Gr1+CD11b+ cells could suppress diabetogenic CD4 and CD8 T cell function in an IL-10–, NO-, and cell contact-dependent manner. Interestingly, single anti-Gr1 mAb treatment can also induce a transient expansion of Gr1+CD11b+ cells that delayed diabetes development in NOD mice. Our data suggest that Gr1+CD11b+ cells contribute to the establishment of immune tolerance to pancreatic islet autoimmunity. Manipulation of Gr1+CD11b+ cells could be considered as a novel immunotherapy for the prevention of type 1 diabetes.

Cite

CITATION STYLE

APA

Hu, C., Du, W., Zhang, X., Wong, F. S., & Wen, L. (2012). The Role of Gr1+ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice. The Journal of Immunology, 188(1), 294–301. https://doi.org/10.4049/jimmunol.1101590

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free